Heart Failure

That is, are they all equally effective?

The toxicity of cancer drugs increasingly causing cardiovascular complications in patients.

No difference found in mortality and cardiac events among patients that were and were not taking beta-blockers after an angioplasty.

Supplemental coenzyme Q10 may be a management option for patients with heart failure.

The FDA has approved Silvergate Pharmaceuticals' Qbrelis, the first lisinopril oral solution.

Heart failure with preserved ejection typically accompanied by hypertension, diabetes, lung disease, or chronic renal failure.

Top news of the day from across the health care landscape.

This article highlights the latest literature surrounding both new and old heart failure therapies.

Approximately 12.3% of patients diagnosed with heart failure were diagnosed with cancer.

Common drugs such as metformin or anesthesia could potentially cause complications for patients with heart failure.

Approximately 38% of women who had initial echocardiograms received a follow-up scan.

The American Heart Association has released a scientific statement cautioning against the use of some common drugs and supplements in patients with heart failure.

Depression affects 10% to 40% of patients with heart failure, depending on disease severity.

The Absorb GT1 Bioresorbable Vascular Scaffold System is the first coronary artery disease stent designed to be absorbed by the body.

Two new analyses have further cemented Entresto's place in heart failure therapy.

Approximately 24 to 25% of patients with type 2 diabetes and heart failure died within 18 months.

Patients with heart failure who have had 3 or more vaccines had a 55% decreased risk of developing dementia.

Fee-for-Service Medicare beneficiaries with heart failure accounted for 55.3% of readmissions.

This article explores recent evidence describing the potential benefits of vitamin D supplementation in patients with heart failure and reduced ejection fraction.

The American College of Cardiology, American Heart Association, and Heart Failure Society of America recently updated guidelines for pharmacological heart failure treatment, focusing specifically on 2 new agents.

Patients with heart failure who exercise show an 18% decreased risk of all-cause mortality compared with patients who do not exercise.

Approximately 25% of patients develop heart failure within 4 years after the patients’ first heart attack.

The American College of Cardiology, the American Heart Association, and the Heart Failure Society of America have updated heart failure guidelines to recommend the use of 2 medications: sacubitril/valsartan (Entresto) and ivabradine (Corlanor).

This article highlights the latest evidence from both the AHA/ACC and ESC guidelines, which were both published this past weekend.

Incretin-based drugs help type 2 diabetes patients reduce blood sugar.